Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective
systemic therapy, as no drug is currently approved by the FDA for its management. We …

Purpose: Patients discontinuing immuno-oncology regimens may experience periods of
disease control without need for ongoing anticancer therapy, but toxicity may persist. We …

Background Among patients with advanced renal cell carcinoma (RCC), those with
sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the …

Background Treatment-free survival (TFS) characterizes disease control after
discontinuation of immune checkpoint inhibitors (ICIs) until subsequent therapy or death. We …

Importance Phase 2 trials and early efficacy end points play a crucial role in informing
decisions about whether to continue to phase 3 trials. Conventional end points, such as …

Overall survival, progression-free survival, objective response/complete response, and
duration of (complete) response are frequently used as the primary and secondary efficacy …

Background Bone metastases (BoMs) are prevalent in patients with metastatic non-small-
cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond to …

In oncology clinical trials, response‐based endpoints (time to response, objective response,
duration of response [DOR]) are commonly used to detect therapeutic effect to support proof …

Objective To evaluate the outcomes of drug-eluting bead transarterial chemoembolization
(DEB-TACE) according to the size of the beads for the treatment of small hepatocellular …

Simple Summary There is a lack of biomarkers for predicting the response to chemotherapy
in gastric cancer (GC). This study investigates the prognostic significance of PD-1 …